Moreover, novel evidence has emerged that ADAM17 can modulate the capability of cancer cells to evade immunosurveillance and driving cancer evasion, by regulating cleavage of crucial immune receptors and ligands in both immune and target cancer cells [161,162]. Here, ADAM17 is linked to cancer.